These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 8323381)

  • 1. Serum osteocalcin and carboxyterminal propeptide of type I procollagen in rheumatoid arthritis.
    Kröger H; Risteli J; Risteli L; Penttilä I; Alhava E
    Ann Rheum Dis; 1993 May; 52(5):338-42. PubMed ID: 8323381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of bone Gla protein (osteocalcin, BGP) and carboxyterminal propeptide of type I procollagen (PICP) in acromegaly: effects of long-term octreotide treatment.
    Terzolo M; Piovesan A; Osella G; Pia A; Reimondo G; Pozzi C; Raucci C; Torta M; Paccotti P; Angeli A
    Calcif Tissue Int; 1993 Mar; 52(3):188-91. PubMed ID: 8481830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of selected bone metabolism markers in rheumatoid arthritis patients.
    Matuszewska A; Szechiński J
    Adv Clin Exp Med; 2013; 22(2):193-202. PubMed ID: 23709375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical markers of bone and collagen turnover in acromegaly or Cushing's syndrome.
    Piovesan A; Terzolo M; Reimondo G; Pia A; Codegone A; Osella G; Boccuzzi A; Paccotti P; Angeli A
    Horm Metab Res; 1994 May; 26(5):234-7. PubMed ID: 8076906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association between insulin-like growth factor 1 (IGF-1), IGF-binding proteins (IGFBPs), and the carboxyterminal propeptide of type I procollagen (PICP) in pre- and postmenopausal women with rheumatoid arthritis.
    Szeremeta A; Jura-Półtorak A; Komosińska-Vassev K; Zoń-Giebel A; Kapołka D; Olczyk K
    Scand J Rheumatol; 2017 May; 46(3):171-179. PubMed ID: 27775453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How useful are bone turnover markers in rheumatoid arthritis? Influence of disease activity and corticosteroid therapy.
    Cortet B; Flipo RM; Pigny P; Duquesnoy B; Racadot A; Boersma A; Delcambre B
    Rev Rhum Engl Ed; 1997 Mar; 64(3):153-9. PubMed ID: 9090763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased serum levels of carboxyterminal propeptide of type 1 collagen (PICP) in hyperthyroidism.
    Legovini P; De Menis E; Da Rin G; Roiter I; Breda F; Artuso V; Di Virgilio R; Conte N
    Horm Metab Res; 1994 Jul; 26(7):334-7. PubMed ID: 7959610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is bone turnover a determinant of bone mass in rheumatoid arthritis?
    Cortet B; Flipo RM; Pigny P; Duquesnoy B; Boersma A; Marchandise X; Delcambre B
    J Rheumatol; 1998 Dec; 25(12):2339-44. PubMed ID: 9858427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type I procollagen propeptide in patients on CAPD: its relationships with bone histology, osteocalcin, and parathyroid hormone.
    Joffe P; Heaf JG; Jensen LT
    Nephrol Dial Transplant; 1995 Oct; 10(10):1912-7. PubMed ID: 8592603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical usefulness of serum carboxyterminal propeptide of procollagen I and tartrate-resistant acid phosphatase determinations to evaluate bone turnover in patients with chronic renal failure.
    López Gavilanes E; González Parra E; de la Piedra C; Caramelo C; Rapado A
    Miner Electrolyte Metab; 1994; 20(5):259-64. PubMed ID: 7700213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gender differences in bone turnover in 2-year-old Thoroughbreds.
    Jackson BF; Lonnell C; Verheyen K; Wood JL; Pfeiffert DU; Price JS
    Equine Vet J; 2003 Nov; 35(7):702-6. PubMed ID: 14649363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modifications of biochemical markers of bone and collagen turnover during corticosteroid therapy.
    Conti A; Sartorio A; Ferrero S; Ferrario S; Ambrosi B
    J Endocrinol Invest; 1996 Feb; 19(2):127-30. PubMed ID: 8778165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type I collagen and procollagen fragments in patients with metabolic bone diseases.
    Lin JS; Kao JT; Tsai KS
    J Formos Med Assoc; 1996 Jul; 95(7):523-9. PubMed ID: 8840753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twenty-four-hour osteocalcin, carboxyterminal propeptide of type I procollagen, and aminoterminal propeptide of type III procollagen rhythms in normal and growth-retarded children.
    Saggese G; Baroncelli GI; Bertelloni S; Cinquanta L; DiNero G
    Pediatr Res; 1994 Apr; 35(4 Pt 1):409-15. PubMed ID: 8047377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Procollagen type I carboxy-terminal propeptide as a marker of osteoblastic bone metastases.
    Francini G; Gonnelli S; Petrioli R; Bruni S; Marsili S; Aquino A; Camporeale A
    Cancer Epidemiol Biomarkers Prev; 1993; 2(2):125-9. PubMed ID: 8467247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum markers of bone and collagen turnover in patients with Cushing's syndrome and in subjects with adrenal incidentalomas.
    Osella G; Terzolo M; Reimondo G; Piovesan A; Pia A; Termine A; Paccotti P; Angeli A
    J Clin Endocrinol Metab; 1997 Oct; 82(10):3303-7. PubMed ID: 9329358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissociation of bone formation markers in bone metastasis of prostate cancer.
    Koizumi M; Maeda H; Yoshimura K; Yamauchi T; Kawai T; Ogata E
    Br J Cancer; 1997; 75(11):1601-4. PubMed ID: 9184174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of bone formation by biochemical markers in metabolic bone disease: separation between osteoblastic activity at the cell and tissue level.
    Charles P; Hasling C; Risteli L; Risteli J; Mosekilde L; Eriksen EF
    Calcif Tissue Int; 1992 Dec; 51(6):406-11. PubMed ID: 1451006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of GH/IGF-I deficiency on bone and collagen turnover in children and adults with GH deficiency].
    Sartorio A; Conti A; Monzani M; Ferrero S; Biella O; Casati G; Faglia G
    Minerva Endocrinol; 1995 Jun; 20(2):135-40. PubMed ID: 8531895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of two years of growth hormone (GH) replacement therapy on bone metabolism and mineral density in childhood and adulthood onset GH deficient patients.
    Longobardi S; Di Rella F; Pivonello R; Di Somma C; Klain M; Maurelli L; Scarpa R; Colao A; Merola B; Lombardi G
    J Endocrinol Invest; 1999 May; 22(5):333-9. PubMed ID: 10401706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.